Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVX70371
- Development stage
- Phase 1
- Lead developer
- AstriVax Therapeutics
- Modality
- Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Parenteral (injection)
01
Overview
AVX70371 is a novel therapeutic vaccine developed by AstriVax Therapeutics for the treatment of chronic hepatitis B virus (HBV) infection. It is based on the proprietary Launch-iT technology platform and utilizes a plasmid-launched live attenuated virus (PLLAV) approach. The vaccine consists of a genetically modified yellow fever 17D viral vector expressing the core protein of HBV (HBc). Upon administration, it induces in vivo production of the live attenuated virus that stimulates robust CD4+ and CD8+ T-cell responses specifically targeting HBV-infected hepatocytes. This immunotherapeutic strategy aims to overcome immune exhaustion seen in chronic HBV patients and could form part of a functional cure when used in combination with other therapies. The drug is currently being evaluated in Phase 1 clinical trials for safety, tolerability, and immunogenicity.
- Other names
- Chronic hepatitis B vaccine - AstriVaxHepatitis B vaccine - AstriVax
02
Targets
HBV-specific TCR (Hepatitis B virus PreS2/core-specific T-cell receptor)
Beyond the preview
Go deeper on AVX70371.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVX70371.